Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy
Chang Song(University of Maryland, Baltimore), Arnob Banerjee(Johnson & Johnson (United States)), Koji Tamada(Yamaguchi University), Kavitha Sadashivaiah(University of Maryland, Baltimore), Aki Furusawa(University of Maryland, Baltimore), Eduardo Dávila(New Mexico State University)
Cited by 20
Related Papers
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
|Nature Immunology|2001|1k